Two Seas Capital LP Sells 4,615,000 Shares of Esperion Therapeutics, Inc. $ESPR

Key Points

• Two Seas Capital LP has reduced its stake in Esperion Therapeutics by 40%, selling 4,615,000 shares during the first quarter, bringing its total ownership to 6,930,871 shares.
• Esperion's stock price has shown volatility, with a one-year low of $0.69 and a high of $3.94, while currently trading at around $2.68.
• Recent earnings reported by Esperion showed higher-than-expected revenue of $82.39 million, with earnings per share beating the consensus estimate by $0.15.

Two Seas Capital LP lessened its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 40.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,930,871 shares of the biopharmaceutical company's stock after selling 4,615,000 shares during the period. Esperion Therapeutics accounts for about 0.3% of Two Seas Capital LP's portfolio, making the stock its 15th largest position. Two Seas Capital LP owned 3.50% of Esperion Therapeutics worth $9,980,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Meridian Wealth Management LLC acquired a new position in Esperion Therapeutics during the 1st quarter worth about $29,000. Crestline Management LP acquired a new stake in Esperion Therapeutics in the 4th quarter valued at about $63,000. Synergy Asset Management LLC increased its position in Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 30,138 shares in the last quarter. Rafferty Asset Management LLC acquired a new stake in Esperion Therapeutics in the 4th quarter valued at about $82,000. Finally, Private Advisor Group LLC increased its position in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock valued at $58,000 after acquiring an additional 10,000 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ESPR has been the subject of several research reports. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Wall Street Zen cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, August 25th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Esperion Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR traded down $0.03 during mid-day trading on Friday, hitting $2.77. The company's stock had a trading volume of 2,171,293 shares, compared to its average volume of 4,950,888. The stock has a market cap of $557.49 million, a price-to-earnings ratio of -5.64, a price-to-earnings-growth ratio of 58.40 and a beta of 0.89. Esperion Therapeutics, Inc. has a one year low of $0.69 and a one year high of $3.94. The company's fifty day simple moving average is $1.79 and its 200-day simple moving average is $1.38.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.15. The company had revenue of $82.39 million for the quarter, compared to analyst estimates of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. On average, sell-side analysts predict that Esperion Therapeutics, Inc. will post -0.29 EPS for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.